Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Japanese Children with Allergic Asthma
NCT01155700Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2010
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Novartis. Primary endpoint: Geometric mean of serum free IgE level at 24 weeks. Started Jun 2010; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT01155700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01155700.